Nathalie Y. R. Agar
Brigham and Women's Hospital
CancerInternal medicineRadiologyPathologyMagnetic resonance imagingOncologyMass spectrometryChemistryIn vitroIn vivoMetabolomicsMass spectrometry imagingGlioblastomaGliomaBlood–brain barrierBrain tumorDrug deliveryCancer researchBiochemistryMedicineBiology
106Publications
32H-index
3,378Citations
Publications 107
Newest
#1Walid M. Abdelmoula (Brigham and Women's Hospital)H-Index: 14
#2Begoña Giménez-Cassina López (Brigham and Women's Hospital)H-Index: 13
Last. Nathalie Y. R. Agar (Brigham and Women's Hospital)H-Index: 32
view all 9 authors...
Mass spectrometry imaging (MSI) is an emerging technology that holds potential for improving, biomarker discovery, metabolomics research, pharmaceutical applications and clinical diagnosis. Despite many solutions being developed, the large data size and high dimensional nature of MSI, especially 3D datasets, still pose computational and memory complexities that hinder accurate identification of biologically relevant molecular patterns. Moreover, the subjectivity in the selection of parameters fo...
Source
#1Sankha S. Basu (Brigham and Women's Hospital)H-Index: 17
#2Sylwia A. Stopka (Brigham and Women's Hospital)H-Index: 10
Last. Melissa Anne Mallory (Brigham and Women's Hospital)H-Index: 8
view all 14 authors...
Optimal resection of breast tumors requires removing cancer with a rim of normal tissue while preserving uninvolved regions of the breast. Surgical and pathological techniques that permit rapid molecular characterization of tissue could facilitate such resections. Mass spectrometry (MS) is increasingly used in the research setting to detect and classify tumors and has the potential to detect cancer at surgical margins. Here, we describe the ex vivo intraoperative clinical application of MS using...
Source
#1Begoña Giménez-Cassina López (Brigham and Women's Hospital)H-Index: 13
#2Ishwar N. Kohale (MIT: Massachusetts Institute of Technology)H-Index: 1
Last. Michael S. Regan (Brigham and Women's Hospital)H-Index: 7
view all 28 authors...
Background null Response to targeted therapy varies between patients for largely unknown reasons. Here, we developed and applied an integrative platform using mass spectrometry imaging (MSI), phosphoproteomics, and multiplexed tissue imaging for mapping drug distribution, target engagement, and adaptive response to gain insights into heterogeneous response to therapy. null Methods null Patient derived xenograft (PDX) lines of glioblastoma were treated with adavosertib, a Wee-1 inhibitor, and tis...
Source
#1Sylwia A. Stopka (Brigham and Women's Hospital)H-Index: 10
#2Ellen A. Wood (GW: George Washington University)H-Index: 1
Last. Akos Vertes (GW: George Washington University)H-Index: 60
view all 8 authors...
In biological tissues, cell-to-cell variations stem from the stochastic and modulated expression of genes and the varying abundances of corresponding proteins. These variations are then propagated to downstream metabolite products and result in cellular heterogeneity. Mass spectrometry imaging (MSI) is a promising tool to simultaneously provide spatial distributions for hundreds of biomolecules without the need for labels or stains. Technological advances in MSI instrumentation for the direct an...
Source
#1Shannon CoyH-Index: 11
#2Jia-Ren LinH-Index: 22
Last. Patrick Y. WenH-Index: 122
view all 15 authors...
Source
#1Sankha S. Basu (Brigham and Women's Hospital)H-Index: 17
#2Nathalie Y. R. Agar (Brigham and Women's Hospital)H-Index: 32
Matrix-assisted laser desorption/ionization (MALDI) mass spectrometry imaging (MSI) is an emerging analytical technique that promises to change tissue-based diagnostics. This article provides a brief introduction to MALDI MSI as well as clinical diagnostic workflows and opportunities to apply this powerful approach. It describes various MALDI MSI applications, from more clinically mature applications such as cancer to emerging applications such as infectious diseases and drug distribution. In ad...
Source
Source
Source
#1Bianca Maria Marin (Mayo Clinic)H-Index: 1
#2Kendra A Porath (Mayo Clinic)H-Index: 1
Last. Jann N. Sarkaria (Mayo Clinic)H-Index: 70
view all 30 authors...
BACKGROUND Antibody drug conjugates (ADCs) targeting the epidermal growth factor receptor (EGFR), such as depatuxizumab mafodotin (Depatux-M), is a promising therapeutic strategy for glioblastoma (GBM) but recent clinical trials did not demonstrate a survival benefit. Understanding the mechanisms of failure for this promising strategy is critically important. METHODS PDX models were employed to study efficacy of systemic vs intracranial delivery of Depatux-M. Immunofluorescence and MALDI-MSI wer...
Source
#1Walid M. Abdelmoula (Brigham and Women's Hospital)H-Index: 14
#2Sylwia A. Stopka (Brigham and Women's Hospital)H-Index: 10
Last. Nathalie Y. R. Agar (Brigham and Women's Hospital)H-Index: 32
view all 9 authors...
Motivation: Mass spectrometry imaging (MSI) provides rich biochemical information in a label-free manner and therefore holds promise to substantially impact current practice in disease diagnosis. However, the complex nature of MSI data poses computational challenges in its analysis. The complexity of the data arises from its large size, high dimensionality, and spectral non-linearity. Preprocessing, including peak picking, has been used to reduce raw data complexity, however peak picking is sens...
Source
This website uses cookies.
We use cookies to improve your online experience. By continuing to use our website we assume you agree to the placement of these cookies.
To learn more, you can find in our Privacy Policy.